March 15, 2024

Launch of “GOBIK Aqueous Suspension Syringes”,
Pertussis, Diphtheria, Tetanus, Inactivated Polioand Hib Combined Vaccine

The Research Foundation for Microbial Diseases of Osaka University(Headquarters:Suita-city,Osaka;

Director

General:

Yoshihiro

Yoneda;hereafter, "BIKEN"), Mitsubishi Tanabe Pharma Corporation (Head Office:Chuo-ku, Osaka; Representative Director: Akihiro Tsujimura; hereafter,"MTPC") and Pfizer Japan Inc. (Head Office: Shibuya-ku, Tokyo; President:
Akihisa

Harada;hereafter,"Pfizer")

announced

that"GOBIK

AqueousSuspension Syringes" (hereafter "GOBIK"), Adsorbed Diphtheria-Purified
Pertussis-Tetanus-Inactivated Polio-Haemophilus type b conjugate Combined
Vaccine, was launched in Japan today.
GOBIK is a vaccine that combined the antigenic components of TETRABIK(adsorbed

diphtheria-purified

pertussis-tetanus-inactivatedpolio[Sabinstrain] combined vaccine) with those of Haemophilus influenzae type b （Hib）.
It is expected that the use of GOBIK will reduce the number of shots of routine
vaccinations and the burden on infants and guardians.
GOBIK is a vaccine jointly developed by BIKEN and MTPC, and was first
approved in Japan as the combination vaccine for five diseases on March 27,2023. GOBIK is manufactured by BIKEN, which has a marketing authorization,
distributed by MTPC and jointly promoted by MTPC and Pfizer.
Routine vaccinations with GOBIK will begin on April 1 this year. BIKEN, MTPC andPfizer will continue to contribute to public health in Japan through the manufacture,stable supply and promotion of GOBIK.

1◆Contact information
Mitsubishi Tanabe Pharma Corporation (Mitsubishi Chemical Group,
Corporate Communications Div., Osaka Corporate Communications Dept.)+81-6-6205-5119
Public Relations Section, The Research Foundation for Microbial Diseases ofOsaka University+81-6-6877-4802◆About Research Foundation for Microbial Diseases of Osaka University
The BIKEN Foundation is engaged in the research, development, and supply of vaccinesand provides advanced laboratory test services. As a pioneer of university ventures, theBIKEN Foundation has contributed to public health since its establishment in 1934 based onits mission “Protect the precious lives of people around the world through excellent vaccines.”
Toward a healthy society, the BIKEN Foundation will continue to pursue achievements withits proprietary research and development expertise and biotechnologies to meet society’sexpectations.
https://www.biken.or.jp/english◆About Mitsubishi Tanabe Pharma Corporation
Mitsubishi Tanabe Pharma Corporation (MTPC), the pharma arm of Mitsubishi
Chemical Group (MCG), is one of the oldest pharmaceutical companies in the world,
founded in 1678, and focusing on ethical pharmaceuticals. MTPC is headquarteredin Dosho-machi, Osaka, the birthplace of Japan’s pharmaceutical industry. MCG has
positioned health care as its strategic focus in its management policy, “Forging thefuture”. MTPC sets the MISSION of “Creating hope for all facing illness”. To that end,
MTPC is working on the disease areas of central nervous system, immunoinflammation, diabetes and kidney, and cancer. MTPC is focusing on “precisionmedicine” to provide drugs with high treatment satisfaction by identifying patient
populations with high potential for efficacy and safety. In addition, MTPC is working
to develop “around the pill solutions” to address specific patient concerns based ontherapeutic medicine, including prevention of diseases, pre-symptomatic diseasecare, prevention of aggravation and prognosis. For more information, go tohttps://www.mt-pharma.co.jp/e/◆About Pfizer
At Pfizer, we apply science and our global resources to bring therapies to people
that extend and significantly improve their lives. We strive to set the standard for2

quality, safety, and value in the discovery, development, and manufacture of healthcare products, including innovative medicines and vaccines. Every day, Pfizer
colleagues work across developed and emerging markets to advance wellness,prevention, treatments, and cures that challenge the most feared diseases of ourtime. Consistent with our responsibility as one of the world's premier innovative
biopharmaceuticalcompanies,

wecollaborate

withhealthcare

providers,

governments, and local communities to support and expand access to reliable,
affordable health care around the world. For more than 175 years, Pfizer has worked
to make a difference for all who rely on us. For more information, go towww.pfizer.com (Pfizer Inc.), www.pfizer.co.jp、Instagram、X（Pfizer Japan Inc.）

3